Lenalid Lenalidomide – 5 mg, 10 mg, 15 mg, 25 mg Capsules (1 pack / 30 caps)

At a Glance

Generic Name: Lenalidomide

Brand Name: Lenalid

Strength & Pack Options: Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg, Lenalid 25 mg – each 1 pack / 30 capsules

Dosage Form: Oral tablets for systemic use

Therapeutic Class: Immunomodulatory and anticancer agent (IMiD)

Main Indications: Multiple myeloma, selected myelodysplastic syndromes and mantle cell lymphoma as indicated

Use in Therapy: Combination or maintenance chemotherapy regimens under haematology or oncology supervision

Prescription Status: Prescription-only cytotoxic and teratogenic medicine

Supplied By: Licensed manufacturers and authorised distributors

Storage: Store below 25 °C in a dry place away from light and moisture

Product Description

Lenalid is a range of generic lenalidomide tablets available in four strengths:
Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg, each supplied as
1 pack / 30 tablets. Lenalidomide is an immunomodulatory and anticancer medicine used mainly in the treatment of
multiple myeloma and other haematological conditions. It is given as part of protocol-based chemotherapy or maintenance regimens
designed by specialist haematologists and oncologists.

In multiple myeloma, lenalidomide is widely used in combination with other agents such as dexamethasone and proteasome inhibitors,
and as maintenance therapy after frontline treatment or transplant. The availability of
Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets allows your team to match the
strength and total daily dose to the specific cycle, kidney function and tolerance over time. Lower strengths such as
Lenalid 5 mg and Lenalid 10 mg are often used in maintenance regimens or myelodysplastic syndromes, while higher strengths like
Lenalid 25 mg and Lenalid 15 mg may be used during induction or consolidation according to recognised protocols.

As a generic lenalidomide 5 mg / 10 mg / 15 mg / 25 mg product, Lenalid contains the same active ingredient as originator lenalidomide but may offer
a more accessible option in USD for long-term therapy. Each pack of Lenalid lenalidomide tablets is supplied in sealed blisters with clear labelling of strength,
batch number and expiry date. Generic Meds Mart sources Lenalid only from licensed manufacturers and authorised distributors that comply with recognised GMP standards.

When you buy Lenalid online from Generic Meds Mart, you remain under the care of your own haematology or oncology team.
We do not design or modify chemotherapy regimens; our role is to provide structured access to Lenalid 5 mg, Lenalid 10 mg,
Lenalid 15 mg and Lenalid 25 mg tablets exactly as specified in your written treatment plan.

Key Uses

Lenalid lenalidomide tablets in 5 mg, 10 mg, 15 mg and 25 mg strengths are typically used for the following indications under specialist supervision:

• Multiple myeloma in combination regimens and as long-term maintenance therapy
• Selected myelodysplastic syndromes, particularly with specific cytogenetic profiles
• Mantle cell lymphoma and other haematological malignancies where lenalidomide is recommended
• Maintenance therapy following autologous stem cell transplant or frontline treatment, often using Lenalid 10 mg or Lenalid 5 mg

Your specialist will determine which strength – Lenalid 25 mg, Lenalid 15 mg, Lenalid 10 mg or Lenalid 5 mg – is appropriate at each stage of your regimen.

How Lenalidomide Works in Chemotherapy

Lenalidomide is a second-generation immunomodulatory drug (IMiD) with multiple mechanisms of action.
Although often discussed alongside oral chemotherapy, Lenalid lenalidomide acts differently from traditional cytotoxic agents.
It modifies the immune response, influences the bone marrow microenvironment and directly affects malignant plasma cells.

Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets can enhance T-cell and natural killer cell activity,
leading to stronger immune-mediated attack on tumour cells. Lenalidomide also interferes with the growth of blood vessels within the marrow and alters cytokine signalling.
At the cellular level, lenalidomide binds to specific proteins that control degradation of key transcription factors, promoting apoptosis of malignant plasma cells.

These combined effects make lenalidomide a central component of modern multiple myeloma chemotherapy and maintenance regimens,
but they also explain some of its side effects, such as bone marrow suppression and increased clotting risk.

Dosage & Administration

Dosing of Lenalid is highly individual and must always follow the protocol set by your haematology or oncology team.
The choice among Lenalid 25 mg, Lenalid 15 mg, Lenalid 10 mg and Lenalid 5 mg depends on indication, kidney function,
combination partners and tolerance.

• Lenalid lenalidomide tablets are usually given in 28-day cycles, with treatment days and rest days clearly defined in your calendar.
• Take Lenalid tablets by mouth once daily on the prescribed days, with water, at approximately the same time each day.
• Swallow Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets whole; do not crush, split or chew them unless instructed.
• Follow the cycle plan, including blood test dates and clinic visits, exactly as given.
• If you miss a dose, follow instructions from your treatment centre; do not double the next dose without explicit advice.

Your doctor may reduce the dose from Lenalid 25 mg to Lenalid 15 mg, Lenalid 10 mg or Lenalid 5 mg if blood counts fall,
kidney function changes or side effects emerge.

Precautions

Lenalidomide is strongly teratogenic and requires strict safety measures. Before taking Lenalid, inform your care team about your full medical history and all medicines you use. Key precautions include:

• Pregnancy prevention: Women who are pregnant or may become pregnant must not take Lenalid lenalidomide tablets. Contraception and regular pregnancy testing are often mandatory.
• Blood clots: Lenalid increases the risk of deep vein thrombosis and pulmonary embolism, particularly when combined with steroids.
• Low blood counts: Neutropenia, anaemia and thrombocytopenia are common, especially at higher doses such as Lenalid 25 mg or Lenalid 15 mg.
• Infection risk: Fever or signs of infection during Lenalid therapy require urgent medical assessment.
• Kidney function: Dose adjustments between Lenalid 5 mg, 10 mg, 15 mg and 25 mg are often needed in renal impairment.
• Drug interactions: Your team must know about all prescription medicines, over-the-counter products and supplements you are taking.

Lenalidomide Side Effects

Common side effects

Common side effects of Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg can include:

• Neutropenia and increased infection risk
• Thrombocytopenia with bruising or bleeding
• Anaemia, tiredness and shortness of breath
• Mild nausea, constipation or diarrhea
• Rash or mild skin reactions
• Muscle cramps, weakness and fatigue
• Mild peripheral neuropathy (tingling or numbness in hands and feet)

Many of these effects are managed through blood test monitoring, dose reductions and supportive care.

Serious side effects

Serious side effects of lenalidomide require urgent medical attention and may include:

• Signs of blood clots: chest pain, sudden shortness of breath, coughing blood, painful swollen leg
• High fever, chills or severe infection symptoms
• Severe skin reactions, blistering or extensive rash
• Marked bleeding or bruising, nosebleeds or blood in urine or stools
• Sudden confusion, visual changes or neurological symptoms

If you experience any of these reactions while taking Lenalid lenalidomide tablets, seek emergency care immediately and contact your treatment centre.

Storage

• Store Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg tablets at room temperature below 25 °C.
• Keep tablets in original blisters and cartons, protected from moisture and light.
• Keep all lenalidomide tablets away from children, pregnant women and anyone not involved in your care.
• Do not use after the expiry date printed on the packaging.

Ask your pharmacist or oncology centre how to safely dispose of unused or expired Lenalid.

Why Buy from Generic Meds Mart

Generic Meds Mart provides reliable access to Lenalid 5 mg, Lenalid 10 mg, Lenalid 15 mg and Lenalid 25 mg lenalidomide tablets
at transparent prices in USD. We source only from licensed manufacturers and authorised distributors that comply with recognised GMP standards.

When you buy Lenalid online from Generic Meds Mart, you benefit from:

• All key lenalidomide strengths on one variable product page (5 mg, 10 mg, 15 mg, 25 mg)
• Plain, discreet outer packaging for international delivery
• Tracked shipping options to many destinations
• Clear, structured product information to support discussions with your haematology or oncology team
• Customer support for ordering, payment and delivery questions

Order Now

Lenalid lenalidomide tablets are prescription-only cytotoxic and teratogenic medicines and must be used strictly under specialist supervision.
Before you order Lenalid 5 mg, 10 mg, 15 mg or 25 mg online, ensure that your haematologist or oncologist has confirmed the indication, dose and cycle length.

Select the required strength – Lenalid 5 mg (1 pack / 30 tablets), Lenalid 10 mg (1 pack / 30 tablets),
Lenalid 15 mg (1 pack / 30 tablets) or Lenalid 25 mg (1 pack / 30 tablets) – add it to your cart and complete the secure checkout on
Generic Meds Mart. Your order will be processed, packed discreetly and shipped with tracking where available. All treatment decisions, dose changes and monitoring remain the responsibility of your healthcare team.

Carfilnat 60 mg Carfilzomib Injection (1 vial)

At a Glance

Generic Name: Carfilzomib

Brand Name: Carfilnat

Strength & Pack Size: 60 mg carfilzomib per vial; 1 vial

Dosage Form & Route: Lyophilised powder for IV infusion after reconstitution and dilution

Therapeutic Class: Proteasome inhibitor (targeted anticancer therapy), injectable chemotherapy

Primary Indication: multiple myeloma in adults where carfilzomib-based therapy is appropriate

Usual Adult Dose: Dose and schedule are individualized and defined by your oncologist; administered in cycles in a clinic or hospital

Prescription Status: Prescription-only medicine (specialist use)

Storage: Store as directed on the vial/carton label; typically refrigerated (2–8 °C), protected from light, and not frozen

Product Description

Carfilnat 60 mg contains carfilzomib, an intravenous proteasome inhibitor used in adult multiple myeloma when your hematology–oncology specialist determines that a carfilzomib-based regimen is appropriate. This product is supplied as a single 60 mg vial of lyophilised powder that must be reconstituted and diluted before IV infusion by trained professionals. Carfilzomib is not a self-administered medicine and should only be used within a confirmed diagnosis, a specialist-led treatment plan, and an agreed schedule of clinic visits and laboratory monitoring.

In multiple myeloma care, treatment choices depend on prior therapies, response history, kidney and heart function, infection risk, and the overall goal of therapy. Carfilzomib may be used in combination regimens with other anticancer agents and supportive medicines, with cycle length and duration defined by local protocols and your specialist’s judgement. Because dosing is individualized and adverse effects can be serious, patients should never start, stop, or alter therapy without clinical supervision.

Generic Meds Mart supplies Carfilnat 60 mg carfilzomib injection in original manufacturer packaging sourced through licensed distribution channels. The vial and carton typically display the brand name, strength, active ingredient, batch number, and expiry date to support verification by hospital pharmacies and oncology clinics upon receipt. Orders are processed with secure checkout, shipped in discreet outer packaging, and may be delivered internationally where regulations allow.

Key Uses

Carfilnat 60 mg is used for multiple myeloma in adults when a proteasome inhibitor strategy is clinically appropriate and prescribed by an oncologist. It is commonly selected for patients who require treatment beyond initial therapy or whose disease has returned, but the exact line of therapy depends on individual factors and local guidance.

• multiple myeloma regimens where IV carfilzomib is used with specialist monitoring and supportive care
• Combination approaches where carfilzomib is paired with corticosteroids and/or other anticancer medicines according to protocol
• Situations where an oncology team needs a planned vial supply to match cycle scheduling and pharmacy preparation

How Carfilzomib Works in Chemotherapy

Carfilzomib targets the proteasome, a protein complex that helps cells break down damaged or unneeded proteins. Myeloma cells often rely on high proteasome activity to manage protein stress and maintain survival. By inhibiting proteasome function, carfilzomib increases the build-up of misfolded proteins inside malignant plasma cells, disrupts critical signaling pathways, and can trigger programmed cell death when used consistently within an oncology regimen.

This mechanism is different from classic DNA-damaging cytotoxic drugs and is considered targeted therapy within the broader chemotherapy setting. Even so, carfilzomib affects normal tissues and can cause clinically significant toxicities, so careful monitoring remains essential. Your team may follow blood counts, kidney function, blood pressure, and symptoms of heart or lung complications to balance benefit and safety throughout treatment.

Dosage & Administration

Carfilnat 60 mg is administered by IV infusion in a clinic or hospital by trained healthcare professionals. Your oncologist determines the dose, infusion duration, cycle schedule, and total number of cycles based on your diagnosis, prior treatments, tolerability, and organ function. Patients should not attempt to reconstitute, dilute, or administer carfilzomib themselves, and the medicine must be prepared using appropriate cytotoxic handling procedures.

Hydration plans, premedication, and supportive medicines may be used depending on your protocol and risk profile. Because interactions and comorbidities can influence safety, always provide a complete list of prescription medicines, over-the-counter products, and supplements to your oncology team. If an infusion is missed or delayed, only your treating specialists can decide how to adjust the schedule; do not attempt to compensate by changing future doses on your own.

Precautions

Carfilzomib can affect the heart and blood vessels. Patients with a history of heart failure, coronary disease, arrhythmias, or uncontrolled hypertension may require additional evaluation and monitoring. Report new or worsening shortness of breath, chest pain, swelling of the legs, sudden weight gain, dizziness, or fainting promptly, as these can signal cardiovascular or fluid-balance complications.

Infections and blood count changes may occur during therapy, including neutropenia, anemia, and thrombocytopenia, which can increase the risk of fever, bleeding, bruising, and fatigue. Kidney function can worsen in some patients, and dehydration or tumour lysis risk may require preventive measures depending on disease burden. Tell your team immediately if you develop fever, chills, severe weakness, confusion, reduced urine output, unusual bleeding, or any rapidly worsening symptoms.

Carfilzomib Side Effects

Common side effects

Common carfilzomib side effects can include fatigue, nausea, diarrhea or constipation, decreased appetite, fever, headache, shortness of breath, cough, swelling, and changes in blood counts seen on laboratory tests. Some patients experience infusion-related symptoms such as chills or body aches, and blood pressure changes can occur during treatment.

• Fatigue, weakness, fever, or flu-like symptoms
• Nausea, vomiting, diarrhea, constipation, or reduced appetite
• Anemia, thrombocytopenia, or neutropenia noted on blood tests
• Shortness of breath, cough, or swelling that should still be reported to your team

Serious side effects

Serious side effects require urgent medical attention and can include heart failure, heart attack, severe hypertension, serious arrhythmias, severe shortness of breath, blood clots, severe infections, clinically significant bleeding, tumour lysis syndrome, or severe kidney or liver injury. Rare but severe conditions such as thrombotic microangiopathy and severe pulmonary complications have been reported with proteasome inhibitor therapy.

• Chest pain, severe shortness of breath, fainting, or new irregular heartbeat
• High fever, signs of sepsis, or persistent infection symptoms
• Uncontrolled bleeding, black stools, or severe bruising
• Confusion, sudden weakness, reduced urine output, or severe dehydration symptoms

Storage

Carfilnat 60 mg should be stored as directed on the carton and vial label. In many settings, unopened vials are kept refrigerated at 2–8 °C and protected from light, and they should not be frozen. Preparation, reconstitution, dilution, and disposal are typically handled by a hospital pharmacy or infusion centre according to cytotoxic regulations and local protocols.

Patients are rarely expected to store carfilzomib at home; if transport is required, follow written instructions from your clinic and keep the medicine in its original packaging until it is received by the treatment centre.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for oncology medicines such as Carfilnat 60 mg carfilzomib injection. We supply products in original packaging sourced through licensed channels, with batch and expiry details available for verification by pharmacies and clinics. Pricing is displayed in USD to support planning for multi-cycle treatment, and orders are processed through secure checkout.

Shipments are packed in discreet outer cartons, and tracked or international delivery options may be available where regulations allow. Generic Meds Mart does not replace your treating oncologist. Decisions about whether carfilzomib is appropriate, how it is combined with other medicines, and how side effects are managed must be made by qualified healthcare professionals.

Order Now

Before you buy Carfilnat 60 mg online from Generic Meds Mart, you should have a confirmed diagnosis of multiple myeloma and a treatment plan agreed with your oncology team, including the intended regimen, cycle schedule, and monitoring plan. Your clinic can estimate how many vials are needed for planned cycles and help confirm the correct strength and pack size before ordering.

Once your plan is confirmed, select Carfilnat 60 mg (1 vial), add it to your cart, and complete secure checkout in USD. Orders are dispatched in discreet packaging with delivery options where available, but any questions about carfilzomib dosage, missed infusions, or carfilzomib side effects must be directed to your treating team rather than managed independently.

FAQ about Carfilnat (Carfilzomib)

Q1: What is Carfilnat 60 mg used for?

Carfilnat 60 mg contains carfilzomib, a proteasome inhibitor used in adult multiple myeloma when prescribed by an oncologist as part of a specialist-led regimen.

Q2: Is Carfilnat a tablet or an infusion?

Carfilnat is not a tablet. It is a vial that must be reconstituted, diluted, and given by IV infusion by trained professionals in a clinic or hospital setting.

Q3: How often are carfilzomib infusions given?

Carfilzomib is administered in cycles, and the exact infusion days and number of cycles depend on your protocol, combination medicines, and your response and tolerance. Only your oncologist can define the correct schedule.

Q4: What monitoring is usually needed during treatment?

Monitoring often includes blood counts, kidney function tests, blood pressure checks, and clinical assessment for infection, bleeding, and heart or lung symptoms. Your team will set the frequency based on your individual risk profile and regimen.

Q5: What should I do if an infusion is delayed or missed?

Do not try to adjust doses on your own. Contact your oncology team promptly so they can decide how to reschedule the infusion safely within your treatment plan.

Bendit Bendamustine – 100 mg Injection (1 vial)

At a Glance

Generic Name: Bendamustine Hydrochloride

Brand Name: Bendit

Strength & Pack: 100 mg per vial, 1 vial

Dosage Form & Route: Lyophilised powder for IV infusion after reconstitution

Therapeutic Class: Alkylating antineoplastic (nitrogen mustard derivative)

Primary Indications: Chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL) where bendamustine-based regimens are appropriate

Typical Use in Therapy: Given in cycles under specialist haematology–oncology supervision, often combined or sequenced with other systemic agents

Mode of Action: DNA cross-linking alkylating agent with purine-like structure leading to apoptosis of malignant lymphocytes

Key Benefits: Established option in CLL and indolent NHL protocols with proven efficacy in guideline-based regimens

Precautions: Myelosuppression, infection risk, infusion reactions, organ toxicity and potential long-term secondary malignancy risk

Storage: Store in original cytotoxic packaging as per local product information; hospital pharmacy manages reconstitution and disposal

Product Description

Bendit 100 mg contains bendamustine hydrochloride, an alkylating antineoplastic agent used in the treatment of chronic lymphocytic leukemia (CLL) and certain types of indolent non-Hodgkin lymphoma (NHL) when standard regimens are indicated. This presentation provides a single vial containing 100 mg of bendamustine as a lyophilised powder that must be reconstituted and further diluted before intravenous infusion. Bendit is designed exclusively for use in hospital or specialist infusion-centre settings under the care of experienced haematology–oncology teams.

In modern protocols, bendamustine is often considered when patients require an alkylating backbone that combines DNA cross-linking activity with structural features distinct from older nitrogen mustards. It may be used in first-line regimens for selected CLL or indolent NHL patients, as well as in later lines of therapy depending on regional guidelines and prior treatment history. Bendit 100 mg bendamustine injection is not a tablet or self-administered medicine; it is a cytotoxic hospital-only infusion requiring careful handling, dosing and monitoring.

Generic Meds Mart offers Bendit 100 mg bendamustine injection in original manufacturer cartons with clear cytotoxic labelling. Each vial is supplied with visible strength, batch number and expiry date so hospital pharmacies and infusion centres can verify product identity and maintain accurate treatment records. Outer shipping parcels are neutral and do not mention cancer, lymphoma or chemotherapy on the outside, supporting patient privacy. Our role is limited to structured access and logistics; all clinical decisions about whether to use bendamustine, how to combine it with other drugs and how long to continue therapy rest with your treating specialists.

Key Uses

Within locally approved indications and specialist protocols, Bendit 100 mg bendamustine injection is generally used for adults with chronic lymphocytic leukemia (CLL) when bendamustine-based regimens are appropriate. It may be selected for patients who are not suitable for more intensive strategies or in situations where established evidence supports bendamustine as part of first-line or subsequent-line treatment.

Bendit is also used for indolent non-Hodgkin lymphoma, particularly in settings where disease has not responded adequately to previous rituximab-containing regimens or where bendamustine–antibody combinations are recommended by guidelines. The exact indication, line of therapy and treatment goal are defined by the haematology–oncology team based on disease characteristics, comorbidities and prior therapies. Off-label use in other lymphoid malignancies or conditioning schedules, where practiced, must be guided by up-to-date evidence and local regulations.

How Bendamustine Works in Chemotherapy

Bendamustine, the active ingredient in Bendit 100 mg injection, is an alkylating agent with a unique structure that combines a bifunctional nitrogen mustard group and a benzimidazole ring with purine-like features. After administration, bendamustine forms reactive intermediates that create cross-links within and between DNA strands in dividing cells. These DNA cross-links interfere with replication and transcription, leading to irreparable DNA damage and activation of apoptosis pathways in malignant lymphocytes.

Unlike some classic alkylating agents, bendamustine has been shown in experimental models to trigger multiple mechanisms of cell death and may retain activity in certain settings where cross-resistance to other drugs has emerged. Its S-phase–non-specific profile means that it can damage cells in several phases of the cell cycle, although dividing cells are especially vulnerable. This combination of mechanisms underpins its role in chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma regimens.

Dosage & Administration

All aspects of dosing and administration for Bendit 100 mg bendamustine injection must be determined by experienced haematologists or oncologists following the official product information and current clinical guidelines. The dose is usually calculated according to body surface area, overall treatment plan, organ function, concomitant medicines and prior therapies. Schedules typically involve cyclic administration, with bendamustine given on specific days of each cycle alongside premedication and supportive care as needed.

Before infusion, the lyophilised powder in each Bendit vial is reconstituted with a suitable diluent and then further diluted in an appropriate infusion solution by trained pharmacy or nursing staff. Infusions are performed in settings where patients can be monitored for infusion reactions, blood pressure changes and other acute side effects. Bendit must never be injected undiluted or given by rapid intravenous push, and it is not suitable for self-administration at home. If a planned infusion is missed or delayed, only the treating team can decide how to adjust the schedule.

Precautions

Bendamustine is a potent myelosuppressive agent, and Bendit 100 mg injection can cause significant reductions in white blood cells, red blood cells and platelets. Regular full blood counts are required before and during treatment, and therapy may need to be delayed or adjusted in the event of severe cytopenias. Patients and caregivers should watch for fever, chills, sore throat, unusual bruising, bleeding, extreme fatigue or shortness of breath, and seek immediate medical attention if these occur.

Bendit can also cause infusion-related reactions, including rash, pruritus, flushing, fever or shortness of breath, particularly during early cycles. Liver and kidney function may be affected, and dose modification or additional monitoring may be needed in patients with underlying hepatic or renal impairment. Nausea, vomiting and gastrointestinal upset are common and are usually managed with modern antiemetic regimens and supportive care. Bendamustine is teratogenic and potentially mutagenic; effective contraception is recommended during treatment and for a period afterwards for both patients and partners. It may impair fertility, and patients who are concerned about fertility preservation should discuss options with their care team before starting therapy.

Bendamustine Side Effects

Common side effects

Common bendamustine side effects with Bendit 100 mg injection include neutropenia, thrombocytopenia and anaemia, which can manifest as increased infections, easy bruising, bleeding and tiredness. Many patients experience nausea, vomiting, loss of appetite, diarrhoea or constipation, mild rash or itching, headache and general weakness or malaise. Transient elevations in liver enzymes and mild electrolyte disturbances can appear on blood tests and may not always cause noticeable symptoms.

These common bendamustine side effects are typically managed through protocol-defined supportive care: antiemetics, growth-factor support where appropriate, transfusions, infection prophylaxis or treatment and dose adjustments where needed. Patients should not attempt to continue bendamustine despite significant symptoms without speaking to their treating team, as early intervention can often prevent more serious complications.

Serious side effects

Serious bendamustine adverse effects require urgent specialist attention and may necessitate treatment interruption or discontinuation. These can include severe or prolonged bone marrow suppression with sepsis, severe infections or life-threatening bleeding, severe infusion reactions with chest pain, marked shortness of breath or hypotension, signs of significant liver injury such as jaundice and dark urine, new or worsening kidney problems, and severe skin reactions with blistering, peeling or painful widespread rash.

Over the long term, exposure to bendamustine and other alkylating agents is associated with a risk of secondary malignancies, including therapy-related myelodysplastic syndromes or acute leukaemia, particularly after prolonged or repeated courses. Any new, unexplained changes in blood counts or bone marrow findings after treatment should be carefully evaluated. If patients notice alarming symptoms such as high fever, confusion, difficulty breathing, chest pain, severe rash or uncontrolled bleeding while on Bendit, they must seek emergency medical care and inform clinicians that they are receiving bendamustine.

Storage

Bendit 100 mg bendamustine injection should be stored in its original cytotoxic carton at the temperature specified in the local product information, protected from light and moisture. Hospital or clinic pharmacies are usually responsible for storage, reconstitution, dilution and disposal according to cytotoxic handling regulations. Vials should not be used after the expiry date on the packaging, and any unused product or materials that come into contact with bendamustine must be disposed of as hazardous pharmaceutical waste rather than in normal rubbish. Patients are rarely required to store Bendit at home; if they are asked to transport vials to a treatment centre, they should follow written instructions from the clinic carefully.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on structured access to essential haematology–oncology medicines such as Bendit 100 mg bendamustine injection. We source only from licensed manufacturers and authorised distributors and supply Bendit in original, sealed cytotoxic cartons with strength, batch and expiry details clearly visible. This enables hospital pharmacies and infusion centres to verify product identity as part of their internal safety and documentation procedures.

Prices for Bendit 100 mg are displayed in USD to help patients and clinicians plan treatment budgets for multiple cycles. Orders are shipped in neutral outer packaging with no reference to cancer or chemotherapy, and trackable shipping options are available where regulations allow. Our service is limited to logistics and access; we do not provide personalised medical advice or alter your treatment plan. All decisions about whether to use bendamustine, what dose to use and how long to continue therapy remain entirely with your specialist team.

Order Now

Bendit 100 mg bendamustine injection is a potent chemotherapy medicine that must only be used within carefully controlled haematology–oncology protocols. Before you or your clinic buy Bendit 100 mg online from Generic Meds Mart, your diagnosis, prior therapies, comorbidities and treatment goals should be fully reviewed with your specialist, and a clear bendamustine-based regimen and monitoring plan should be agreed.

Once your care team has defined the protocol, they can calculate how many Bendit 100 mg vials are required for the planned cycles, taking into account possible dose adjustments or treatment delays. The appropriate quantity can then be selected on Generic Meds Mart, added to the cart and checked out securely in USD. Medicines will be dispatched in discreet packaging with tracking where available, but all subsequent questions about bendamustine dosage, bendamustine side effects or regimen changes must be directed to your treating haematology–oncology team rather than managed independently.

FAQ about Bendit (Bendamustine)

Q1: What is Bendit 100 mg used for?
Bendit 100 mg contains bendamustine hydrochloride, an alkylating chemotherapy agent used mainly in adults with chronic lymphocytic leukemia (CLL) and certain indolent non-Hodgkin lymphomas when bendamustine-based regimens are appropriate according to local guidelines and your specialist’s judgement.

Q2: Is Bendit given as a tablet or an infusion?
Bendit 100 mg is not a tablet; it is a lyophilised powder that must be reconstituted and diluted for intravenous infusion by trained staff in a hospital or infusion centre. It is never given by mouth and is not suitable for self-administration at home.

Q3: How often will I receive Bendit infusions?
The frequency and number of Bendit 100 mg bendamustine infusions depend on your disease type, prior treatments and the specific protocol chosen by your haematology–oncology team. Treatment is usually given in cycles, with rest periods between them, and only your specialist can define the exact schedule and number of cycles.

Q4: What monitoring is needed during Bendit treatment?
Patients receiving bendamustine typically require regular full blood counts, kidney and liver function tests and clinical assessments for signs of infection, bleeding, infusion reactions or organ toxicity. Your team will explain which tests are needed, how often they must be done and what symptoms should prompt urgent contact with the clinic.

Q5: Can I drive or work normally while on Bendit?
Many people continue some normal activities during bendamustine treatment, but fatigue, infections or other side effects can limit daily tasks, and responses vary widely. You should follow your specialist’s advice about driving, work and travel, and plan flexibility into your schedule around infusion days and blood-test appointments. Always prioritise safety if you feel unwell, dizzy or unusually tired.

Beedan 50 mg Dasatinib Tablets (1 pack / 60 tabs)

At a Glance

Generic Name: Dasatinib

Brand Name: Beedan 50 mg

Strength & Pack Size: 50 mg tablets, 1 pack / 60 tablets

Dosage Form & Route: Oral film-coated tablets taken by mouth

Therapeutic Class: BCR-ABL tyrosine kinase inhibitor (TKI)

Primary Indications: Chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), as per local label

Typical Use in Therapy: Long-term oral targeted therapy under specialist haematology–oncology supervision

Mode of Action: Inhibits BCR-ABL and related tyrosine kinases to block leukemic cell signalling and proliferation

Key Benefits: Proven efficacy in CML and Ph+ ALL with convenient oral dosing when used appropriately and monitored carefully

Precautions: Requires close monitoring of blood counts, liver function, cardiac status, pleural effusions and drug interactions

Storage: Store below 25 °C in the original blister, protected from moisture and out of reach of children

Product Description

Beedan 50 mg contains dasatinib, an oral BCR-ABL tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) in adults and, in some settings, older children under specialist care. Unlike traditional cytotoxic chemotherapy that indiscriminately targets fast-dividing cells, dasatinib is a targeted therapy designed to block specific signalling pathways that drive leukemic cell growth.

Each pack of Beedan 50 mg dasatinib tablets supplied by Generic Meds Mart contains 60 film-coated tablets, each with 50 mg of dasatinib. The tablets are usually taken once daily, or occasionally in another schedule according to local labels and protocols, with dosing individualised by the treating haematologist based on disease phase, prior therapies, tolerance and response. Because dasatinib can cause clinically significant side effects affecting the blood, lungs, heart and other organs, Beedan 50 mg should never be used without regular specialist follow-up and comprehensive monitoring.

At Generic Meds Mart, Beedan 50 mg dasatinib tablets are sourced only from licensed manufacturers and authorised oncology distributors. Each pack is supplied in its original, sealed blister and carton with visible batch number and expiry date so that hospital pharmacies and clinics can verify the medicine on receipt. Parcels are shipped in neutral outer packaging, without explicit reference to leukemia or targeted therapy, to help preserve patient privacy while maintaining full documentation for medical teams. Our role is to support access and logistics; all clinical decisions about dasatinib dosage, duration and combinations remain with your treating specialists.

Key Uses

Beedan 50 mg dasatinib tablets are used as part of systemic therapy for BCR-ABL–driven leukemias, according to local prescribing information and international guidelines. Typical uses include:

• Treatment of newly diagnosed or previously treated chronic myeloid leukemia (CML) in different phases, where dasatinib is considered an appropriate tyrosine kinase inhibitor option.
• Treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) as part of multi-drug regimens, often combined with chemotherapy or other targeted agents.
• Use in patients who are intolerant of or resistant to other BCR-ABL TKI therapies, where switching to dasatinib is considered clinically appropriate by the haematologist.

The choice to use Beedan 50 mg rather than another TKI depends on disease phase, risk category, prior treatment history, comorbidities, potential for drug interactions and patient-specific factors such as cardiovascular and pulmonary status.

How Dasatinib Works in Chemotherapy

Dasatinib, the active ingredient in Beedan 50 mg, is a potent tyrosine kinase inhibitor that targets the BCR-ABL fusion protein produced by the Philadelphia chromosome abnormality, which is characteristic of most CML cases and many Ph+ ALL cases. The BCR-ABL fusion protein acts as a continuously active kinase, driving uncontrolled proliferation and survival of leukemic cells.

By binding to and inhibiting BCR-ABL, dasatinib interrupts this abnormal signalling, promoting growth arrest and apoptosis (programmed cell death) in leukemic cells that depend on BCR-ABL activity. Dasatinib also inhibits a range of related kinases, including members of the SRC family, which may contribute to its clinical activity in CML and Ph+ ALL. In many patients, consistent dasatinib therapy can induce haematologic, cytogenetic and molecular responses that translate into improved long-term outcomes when treatment is monitored and adjusted appropriately.

Dosage & Administration

Beedan 50 mg dasatinib tablets must be prescribed and monitored by physicians experienced in managing CML and Ph+ ALL. The dose and schedule of dasatinib depend on the indication (CML phase or Ph+ ALL), prior treatment, co-morbidities and concomitant medicines. Tablets are usually taken once daily, with or without food, swallowing them whole with water. Patients are generally advised not to crush, break or chew the tablets.

Certain medicines, particularly strong inhibitors or inducers of CYP3A4 and medicines that significantly alter gastric pH, may interact with dasatinib and require careful management or avoidance. Routine monitoring typically includes full blood counts, liver function tests, assessment for fluid retention and pleural or pericardial effusions, and evaluation of cardiovascular status. Dose adjustments, interruptions or discontinuation may be needed if side effects become problematic or if laboratory markers indicate safety concerns. Patients should follow their specialist’s instructions precisely and should not change the dasatinib dosage on their own.

Precautions

Before starting Beedan 50 mg, the haematology team will evaluate cardiac risk, pulmonary history, bleeding risk, liver and kidney function, concomitant medicines and infection risk. Dasatinib can cause pleural effusions, pulmonary arterial hypertension, fluid retention, thrombocytopenia, neutropenia and bleeding, among other issues, so baseline and ongoing evaluation is essential. Patients with a history of significant heart disease, poorly controlled hypertension or severe lung disease require especially careful assessment and monitoring.

Grapefruit and grapefruit juice are usually discouraged because of interactions with CYP3A4. Because dasatinib can affect platelet function and coagulation, patients should inform medical and dental teams about their treatment before procedures. Effective contraception is generally recommended for people of childbearing potential during dasatinib therapy and for a period after stopping, as dasatinib may harm a developing fetus. Breastfeeding is usually not recommended while taking Beedan 50 mg.

Dasatinib Side Effects

Common side effects

Common dasatinib side effects in patients taking Beedan 50 mg include myelosuppression (low white cells, red cells and platelets), headache, fatigue, nausea, diarrhoea, abdominal discomfort, mild skin rash, joint or muscle pains and fluid retention such as ankle swelling or periorbital puffiness. Many patients also experience mild to moderate infections due to reduced immune reserve. With close monitoring and timely dose adjustments, many of these effects can be managed with supportive care, temporary treatment interruptions or dose modifications.

Serious side effects

Serious dasatinib adverse effects require urgent medical attention and may include severe neutropenia or thrombocytopenia with infections or bleeding, significant pleural effusions or fluid around the lungs, pulmonary arterial hypertension, heart rhythm problems, severe shortness of breath, marked fluid retention, liver injury or gastrointestinal bleeding. Unexplained chest pain, sudden breathlessness, rapid weight gain, confusion, high fever, uncontrollable bleeding or black/tarry stools are all warning signs that demand immediate medical review.

Any new or rapidly worsening symptom while taking Beedan 50 mg dasatinib tablets should be reported promptly to the treating team, and patients should not stop therapy abruptly without specialist advice unless instructed to do so in an emergency.

Storage

Beedan 50 mg tablets should be stored below 25 °C in their original blister inside the outer carton, protected from moisture and direct heat. Tablets should be kept out of sight and reach of children and should not be transferred into unlabelled containers. Medicines must not be used after the expiry date printed on the pack. Unused or expired dasatinib tablets should be returned to a pharmacy or disposed of using an approved medicines disposal route; they should not be thrown into household rubbish or wastewater.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on improving access to essential targeted therapies such as Beedan 50 mg dasatinib tablets for patients with CML and Ph+ ALL. We work only with licensed manufacturers and authorised distributors who follow recognised quality standards and provide full batch traceability. Every pack of Beedan 50 mg is supplied in original, sealed packaging so that your haematology–oncology team and pharmacy can confirm brand, strength, batch number and expiry before dispensing.

Orders are processed in USD through secure checkout, and shipments are placed in discreet, neutral outer boxes without explicit reference to leukemia, dasatinib or cancer medicines. Where available, trackable delivery options help patients and clinics plan refills so that targeted therapy can continue without interruption. Our role is strictly logistical; complex questions about dasatinib dosage, treatment duration, switching to or from other TKIs and combination strategies remain exclusively with your treating specialists.

Order Now

Before you buy Beedan 50 mg online from Generic Meds Mart, you should have a confirmed diagnosis of CML or Ph+ ALL and a clear recommendation from your haematologist or oncologist that dasatinib is the right BCR-ABL inhibitor for your situation. Your team will explain the goals of therapy, planned monitoring, expected time course for response and what to do if side effects occur.

Once this plan is in place, you can select Beedan 50 mg (1 pack / 60 tabs), choose the number of packs that matches your prescription interval and complete secure checkout in USD. Your medicines will be shipped in discreet packaging with appropriate documentation. You should never initiate, adjust or stop dasatinib therapy without specialist guidance, and any worrying symptom during treatment should prompt immediate contact with your medical team. Generic Meds Mart is here to support safe, reliable access to Beedan 50 mg dasatinib tablets while all clinical decisions remain in professional hands.

FAQ about Beedan (Dasatinib)

Q1: What is Beedan 50 mg used for?
Beedan 50 mg contains dasatinib, a BCR-ABL tyrosine kinase inhibitor used under specialist supervision for chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), according to local prescribing information and guidelines.

Q2: Is Beedan 50 mg chemotherapy?
Beedan 50 mg is considered targeted therapy rather than traditional cytotoxic chemotherapy. It works by blocking BCR-ABL and related kinases that drive leukemic cell growth, but it is still a potent anticancer medicine and must be used with the same level of care and monitoring as other systemic treatments.

Q3: How long will I need to take Beedan 50 mg?
Dasatinib therapy is often long term, especially in CML, and may continue for many years if well tolerated and effective. In Ph+ ALL, treatment duration and the role of dasatinib may differ. Only your haematology team can define how long you should remain on Beedan 50 mg based on your response, side effects and evolving evidence.

Q4: Can I take Beedan 50 mg with my other medicines?
Some medicines, particularly those that strongly affect CYP3A4 or stomach acidity, can interact with dasatinib and alter its levels in the body. You should provide your specialist and pharmacist with a full list of prescription drugs, over-the-counter medicines and supplements so they can check for interactions and adjust therapy where needed.

Q5: What should I do if I miss a dose of Beedan 50 mg?
If you forget a dose, the usual advice is to take the next dose at the regularly scheduled time and not to double up tablets to make up for the missed dose. However, specific instructions can vary, so follow the guidance in your patient leaflet and from your care team, and contact them if you are unsure how to proceed after a missed dose.

Q6: Is Beedan 50 mg the same as Sprycel (Generic Sprycel)?
Beedan 50 mg is Generic Sprycel — it contains the same active ingredient (dasatinib) as Sprycel. It’s used for the same purpose at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), tablet appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.